June 2, 2025
eMedClub News
On June 2, Bristol-Myers Squibb (BMS) and BioNTech announced that they had reached an agreement to jointly develop and commercialize BioNTech's bispecific antibody candidate BNT327 (PM8002, acquired from Promab) globally for various types of solid tumors. According to the agreement, BioNTech and BMS will work together to expand and accelerate the development of this clinical candidate.BMS will pay BioNTech 1500 million USDYuanThe down payment, and pay a total of$2 billionNon-contingent anniversary payments. These tax-deductible expenses will be recorded as acquired IPR&D expenses when incurred, with $1.5 billion to be accounted for in the second quarter.In addition, BioNTech will be eligible to receive up to$7.6 billionAdditional development, regulatory and commercial milestone paymentsBioNTech and BMS will jointly bear the development and manufacturing costs in a 50:50 ratio, with certain exceptions. Global profits/losses will be equally shared between BioNTech and BMS.Under the terms of the agreement, the two parties will jointly develop and commercialize BNT327, including the development of BNT327 as a monotherapy and in combination with other products. Both companies have the right to independently develop the application of BNT327 in further indications and combination therapies, including combining BNT327 with their respective pipeline assets.BNT327 is a next-generation bispecific antibody candidate targeting PD-L1 and VEGF-A.In November 2023, BioNTech obtained the rights to develop, manufacture, and commercialize the drug globally (excluding Greater China) for an upfront payment of $55 million, as well as over $1 billion in development, regulatory, and commercial milestone payments, along with tiered sales royalties.In November 2024, BioNTech acquired Promab for $950 million.'%20fill='%23FFFFFF'%3E%3Crect%20x='249'%20y='126'%20width='1'%20height='1'%3E%3C/rect%3E%3C/g%3E%3C/g%3E%3C/svg%3E)
Currently, BNT327 is being evaluated in several ongoing trials.Have clinically treated more than 1,000 patients, including global Phase 3 trials for first-line treatment of extensive-stage small cell lung cancer (ES-SCLC) and non-small cell lung cancer (NSCLC)., these trials have registration potential. A global Phase 3 trial targeting triple-negative breast cancer (TNBC) is planned to be launched by the end of 2025. Preliminary data from ongoing trials highlight the potential of combining two well-validated therapeutic targets, anti-PD-L1 and anti-VEGF-A, into a single molecule to provide synergistic clinical benefits for patients with various tumor types.BioNTech CEO and Co-Founder Prof. Ugur Sahin stated: "We believe BNT327 has the potential to become a cornerstone in foundational immuno-oncology, moving beyond single-mechanism checkpoint inhibitors and expanding into multiple solid tumor indications. Our collaboration with immuno-oncology pioneer BMS aims to accelerate and broadly expand the development of BNT327 to fully realize its potential. Our focus remains on advancing high-impact, pan-tumor initiatives and combination strategies in oncology, with BNT327 complementing our antibody-drug conjugate program and mRNA-based immunotherapies. We are committed to providing truly transformative options for patients in need."Dr. Christopher Boerner, Chairman of the Board and Chief Executive Officer of Bristol-Myers Squibb, stated: "Our extensive experience and expertise in advancing and delivering breakthrough immuno-oncology drugs position BMS well to synergize the potential of BNT327, an asset with tremendous potential to change the standard of care for patients with solid tumors. The science behind BNT327 and its leading clinical status across multiple difficult-to-treat tumor types further support our pursuit of novel mechanisms and diverse drug modalities in oncology, enhancing our growth trajectory. We are deeply impressed by the innovation BioNTech has achieved to date, and we look forward to collaborating to accelerate existing clinical trials and time to market, while expanding the number of potential indications."
https://investors.biontech.de/news-releases/news-release-details/biontech-and-bristol-myers-squibb-announce-global-strategic#:~:text=MAINZ%2C%20Germany%2C%20and%20PRINCETON%2C%20USA%2C%20June%202%2C%202025,bispecific%20antibody%20BNT327%20across%20numerous%20solid%20tumor%20types.
Exciting Live Broadcast Preview
Press and hold to scan the QR code and participate immediately ↓
June 4, 14:00-15:00
Controlled Ice Cryopreservation Technology Provides an Efficient and Safe Precision Cryopreservation Solution for Cell Therapy
June 5th, 19:00-20:30
Focus on Biosafety and Quality Control Innovation in AAV Gene Therapy Products
Statement
This article aims to convey industry development information and explore the frontier progress of biomedicine. The content of the article represents the author's viewpoint and does not represent the position of EMedClub, nor does it constitute any value judgment, investment advice, or medical guidance. If needed, please consult a professional for investment or visit a正规 hospital for medical advice.
Dian Dian "Share”、“Like" and "In Progress"，Give me a little recharge~"
